Jacobson Pharma Corporation Limited

SEHK:2633 Rapport sur les actions

Capitalisation boursière : HK$1.1b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Jacobson Pharma Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Derek Sum

Directeur général

HK$20.8m

Rémunération totale

Pourcentage du salaire du PDG19.6%
Durée du mandat du directeur général8.5yrs
Propriété du PDG60.2%
Durée moyenne d'occupation des postes de directionpas de données
Durée moyenne du mandat des membres du conseil d'administration8.3yrs

Mises à jour récentes de la gestion

Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now

Aug 21
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Recent updates

Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now

Aug 21
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27
Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jun 20
These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Nov 28
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Sep 25
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 28
Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jul 14
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Feb 09
Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Nov 29
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Sep 24
Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Sep 16
Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Feb 03
Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Jan 24
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Jan 11
Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Dec 27
Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Dec 12
Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Dec 03
Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Analyse de la rémunération des PDG

Comment la rémunération de Derek Sum a-t-elle évolué par rapport aux bénéfices de Jacobson Pharma?
DateRémunération totaleSalaireBénéfices de l'entreprise
Mar 31 2024HK$21mHK$4m

HK$186m

Dec 31 2023n/an/a

HK$221m

Sep 30 2023n/an/a

HK$217m

Jun 30 2023n/an/a

HK$234m

Mar 31 2023HK$14mHK$3m

HK$175m

Dec 31 2022n/an/a

HK$207m

Sep 30 2022n/an/a

HK$203m

Jun 30 2022n/an/a

HK$190m

Mar 31 2022HK$5mHK$3m

HK$178m

Dec 31 2021n/an/a

HK$166m

Sep 30 2021n/an/a

HK$154m

Jun 30 2021n/an/a

HK$164m

Mar 31 2021HK$5mHK$4m

HK$174m

Dec 31 2020n/an/a

HK$183m

Sep 30 2020n/an/a

HK$191m

Jun 30 2020n/an/a

HK$203m

Mar 31 2020HK$5mHK$4m

HK$214m

Sep 30 2019n/an/a

HK$273m

Jun 30 2019n/an/a

HK$259m

Mar 31 2019HK$5mHK$4m

HK$245m

Dec 31 2018n/an/a

HK$235m

Sep 30 2018n/an/a

HK$219m

Jun 30 2018n/an/a

HK$211m

Mar 31 2018HK$6mHK$4m

HK$202m

Rémunération vs marché: La rémunération totale de Derek ($USD 2.67M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 235.43K ).

Rémunération et revenus: La rémunération de Derek a augmenté de plus de 20 % au cours de l'année écoulée.


PDG

Derek Sum (61 yo)

8.5yrs

Titularisation

HK$20,779,000

Compensation

Mr. Kwong Yip Sum, also known as Derek, is Non-Executive Chairman of the Board at JBM (Healthcare) Limited since September 22, 2020. He joined the company and its subsidiaries September 22, 2020. With exte...


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Kwong Yip Sum
Chairman8.5yrsHK$20.78m60.18%
HK$ 679.2m
Yue Wai Pun
VP of Administration & Executive Director7.5yrsHK$3.18m0.42%
HK$ 4.7m
Chun Leung Yim
Executive Director8.3yrsHK$6.77m2.04%
HK$ 23.0m
Sing Kwong Lam
Independent Non-Executive Director8.3yrsHK$230.00kpas de données
Chun Man Young
Independent Non-Executive Director8yrsHK$230.00kpas de données
Kwok Chow
Member of Scientific Advisory Committee8.3yrspas de donnéespas de données
Wai Lee
Member of Scientific Advisory Committee8.3yrspas de donnéespas de données
Hoi Yee Tong
Member of Scientific Advisory Committee8.3yrspas de donnéespas de données
Chi Kei Wong
Non-Executive Director & Member of Scientific Advisory Committee8.3yrsHK$230.00kpas de données
Kwing Tong Lam
Independent Non-Executive Director8yrsHK$230.00k0.030%
HK$ 342.0k

8.3yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 2633 sont considérés comme expérimentés (ancienneté moyenne 8.3 ans).